{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:52:33Z","timestamp":1791258753183,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jchf.2026.103310","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:07:54Z","timestamp":1788404874000},"page":"103310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining Clinically Meaningful Within-Patient Changes in Heart Failure"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-4778","authenticated-orcid":false,"given":"Amin","family":"Yehya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-9191","authenticated-orcid":false,"given":"Rebecca","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-2737","authenticated-orcid":false,"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-3731","authenticated-orcid":false,"given":"Nosheen","family":"Reza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Tapaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-0527","authenticated-orcid":false,"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell A.","family":"Psotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cowger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2026.103310_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79(17)","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007564","article-title":"Defining a clinically important change in 6-minute walk distance in patients with heart failure and mitral valve disease","volume":"14","author":"Jain","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jchf.2022.03.003","article-title":"Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF","volume":"10","author":"Butler","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","article-title":"Monitoring clinical changes in patients with heart failure: a comparison of methods","volume":"150","author":"Spertus","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2026.103310_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/ejhf.2981","article-title":"Palliative care in heart failure guidelines: a comparison of the 2021 ESC and the 2022 AHA\/ACC\/HFSA guidelines on heart failure","volume":"25","author":"Blum","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10741-017-9631-6","article-title":"Decision making in advanced heart failure: bench, bedside, practice, and policy","volume":"22","author":"Matlock","year":"2017","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2026.103310_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamacardio.2024.4470","article-title":"Interpreting population mean treatment effects in the Kansas City cardiomyopathy questionnaire: a patient-level meta-analysis","volume":"10","author":"Abdel Jawad","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib11","unstructured":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making: guidance document, April 2023, U.S. Food and Drug Administration. Accessed August 25, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory"},{"key":"10.1016\/j.jchf.2026.103310_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/77.4.371","article-title":"Clinical significance consensus meeting G. methods to explain the clinical significance of health status measures","volume":"77","author":"Guyatt","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jchf.2026.103310_bib13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103310_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.120.047086","article-title":"Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial","volume":"142","author":"Butler","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib15","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.122.059282","article-title":"Health status trajectories before and after hospitalization for heart failure","volume":"145","author":"Vaduganathan","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.006168","article-title":"Systemizing the evaluation of acute heart failure in the emergency department: a quality improvement initiative","volume":"13","author":"Hejjaji","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2026.103310_bib17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamasurg.2024.0718","article-title":"Placebo control and blinding in randomized trials of procedural interventions: a systematic review and meta-regression","volume":"159","author":"Rajkumar","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jchf.2026.103310_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jacc.2022.04.045","article-title":"Analysis of worsening heart failure events in an integrated health care system","volume":"80","author":"Ambrosy","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib19","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/ehf2.14829","article-title":"Applying natural language processing to identify emergency department and observation encounters for worsening heart failure","volume":"11","author":"Hamilton","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2023.09.030","article-title":"Standardized definitions for evaluation of acute decompensated heart failure therapies: HF-ARC expert panel paper","volume":"12","author":"Lala","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib21","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jchf.2021.01.014","article-title":"Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"9","author":"Vaduganathan","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib23","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib24","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.123.066506","article-title":"Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial","volume":"148","author":"Chatur","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib25","first-page":"1086","article-title":"American Society of Echocardiography recommendations for use of echocardiography in clinical trials","volume":"17","author":"Gottdiener","year":"2004","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.echo.2009.05.020","article-title":"Echocardiographic imaging in clinical trials: American Society of Echocardiography standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation","volume":"22","author":"Douglas","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.echo.2019.01.003","volume":"32","author":"Zoghbi","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ejechocard\/jeq030","article-title":"European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease)","volume":"11","author":"Lancellotti","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ejechocard\/jeq031","article-title":"European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)","volume":"11","author":"Lancellotti","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2022.06.002","article-title":"Standardized definitions for bioprosthetic valve dysfunction following aortic or mitral valve replacement: JACC State-of-the-Art Review","volume":"80","author":"Pibarot","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib34","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jacc.2015.05.049","article-title":"Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium","volume":"66","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib35","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jacc.2023.08.008","article-title":"Tricuspid valve academic research consortium definitions for tricuspid regurgitation and trial endpoints","volume":"82","author":"Hahn","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib37","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.echo.2023.04.011","article-title":"Normal values of three-dimensional right ventricular size and function measurements: results of the world alliance societies of echocardiography study","volume":"36","author":"Addetia","year":"2023","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib38","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0735-1097(99)00396-4","article-title":"Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study","volume":"34","author":"Palmieri","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib40","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.hlc.2024.06.158","article-title":"Left atrial volume index by echocardiography\u2014improved, objective, and simplified cutoff values for abnormality based on association with survival","volume":"33","author":"Fung","year":"2024","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jchf.2026.103310_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.121.013836","article-title":"Hemodynamic determinants of left atrial strain in symptomatic patients with significant primary mitral regurgitation","volume":"15","author":"Pournazari","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2026.103310_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: recommendations from the American Society of Echocardiography","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100879","article-title":"Prediction of the individual aortic stenosis progression rate and its association with clinical outcomes","volume":"3","author":"Venema","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jchf.2026.103310_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.echo.2020.11.015","article-title":"Excess mortality associated with progression rate in asymptomatic aortic valve stenosis","volume":"34","author":"Benfari","year":"2021","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib45","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.echo.2023.04.011","article-title":"Normal values of three-dimensional right ventricular size and function measurements: results of the world alliance societies of echocardiography study","volume":"36","author":"Addetia","year":"2023","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2026.103310_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2022.06.002","article-title":"Standardized definitions for bioprosthetic valve dysfunction following aortic or mitral valve replacement: JACC state-of-the-art review","volume":"80","author":"Pibarot","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jacc.2015.05.049","article-title":"Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium","volume":"66","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib48","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jacc.2023.08.008","article-title":"Tricuspid valve academic research consortium definitions for tricuspid regurgitation and trial endpoints","volume":"82","author":"Hahn","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib49","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1093\/eurheartj\/ehad510","article-title":"Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases","volume":"44","author":"Benz","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.103310_bib50","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2589-7500(20)30267-3","article-title":"Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: a comparison with human test-retest performance","volume":"3","author":"Augusto","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jchf.2026.103310_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53697-y","article-title":"Reduction in left ventricular ejection fraction is associated with subsequent cardiac events in outpatients with chronic heart failure","volume":"9","author":"Okuhara","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2026.103310_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48685-1","article-title":"Effect of comprehensive initial training on the variability of left ventricular measures using fast-SENC cardiac magnetic resonance imaging","volume":"9","author":"Lapinskas","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2026.103310_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132687","article-title":"Left ventricular size and heart failure: a cardiac MRI assessment of 38,129 individuals from the UK biobank","volume":"419","author":"Rowe","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib54","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(18)33207-0","article-title":"Multimodality imaging in ischaemic heart failure","volume":"393","author":"Bax","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.103310_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41598-020-79729-6","article-title":"Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction","volume":"11","author":"Garg","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2026.103310_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56213-4","article-title":"Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2026.103310_bib57","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02225-2022","article-title":"Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension","volume":"62","author":"Alabed","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2026.103310_bib58","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s00330-025-11909-2","article-title":"Comprehensive cardiac magnetic resonance assessment of right ventricular and left atrial function for early diagnosis of heart failure with preserved ejection fraction","volume":"36","author":"Lin","year":"2026","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jchf.2026.103310_bib59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/CIRCULATIONAHA.119.045409","article-title":"Altered hemodynamics and end-organ damage in heart failure: impact on the lung and kidney","volume":"142","author":"Verbrugge","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/SHK.0000000000001052","article-title":"Cardiogenic shock due to end-stage heart failure and acute myocardial infarction: characteristics and outcome of temporary mechanical circulatory support","volume":"50","author":"Lim","year":"2018","journal-title":"Shock"},{"key":"10.1016\/j.jchf.2026.103310_bib61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.healun.2023.09.014","article-title":"Heart failure related cardiogenic shock: an ISHLT consensus conference content summary","volume":"43","author":"Kanwar","year":"2024","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jchf.2026.103310_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2022.100120","article-title":"Advances in the staging and phenotyping of cardiogenic shock: part 1 of 2","volume":"1","author":"Jentzer","year":"2022","journal-title":"JACC Adv"},{"key":"10.1016\/j.jchf.2026.103310_bib63","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/clc.24080","article-title":"Patients hospitalized with acute heart failure, worsening renal function, and persistent congestion are at high risk for adverse outcomes despite current medical therapy","volume":"46","author":"Cooper","year":"2023","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib64","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/eurheartj\/ehs444","article-title":"Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial","volume":"34","author":"Ambrosy","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.103310_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007099","article-title":"Invasive hemodynamic assessment and classification of in-hospital mortality risk among patients with cardiogenic shock","volume":"13","author":"Thayer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib66","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cardfail.2021.08.010","article-title":"Heart failure-related cardiogenic shock: pathophysiology, evaluation and management considerations: review of heart failure-related cardiogenic shock","volume":"27","author":"Abraham","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib67","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2015.11.012","article-title":"Hemodynamic predictors of heart failure morbidity and mortality: fluid or flow?","volume":"22","author":"Cooper","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.563853","article-title":"Right atrial pressure is associated with outcomes in patient with cardiogenic shock receiving acute mechanical circulatory support","volume":"8","author":"Davila","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jchf.2026.103310_bib69","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.108.783910","article-title":"Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures","volume":"118","author":"Zile","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib70","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003594","article-title":"Intracardiac pressures measured using an implantable hemodynamic monitor: relationship to mortality in patients with chronic heart failure","volume":"10","author":"Zile","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012754","article-title":"Relationship between remote, ambulatory pulmonary artery pressures, and all-cause mortality in patients with chronic heart failure","volume":"18","author":"Zile","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib72","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.103310_bib73","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"Abraham","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.103310_bib74","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008446","article-title":"Association between change in ambulatory hemodynamic pressures and symptoms of heart failure","volume":"14","author":"Nassif","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib75","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib76","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2026.103310_bib77","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2015.07.067","article-title":"Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction","volume":"66","author":"Borlaug","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib78","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCRESAHA.116.309184","article-title":"Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction","volume":"119","author":"Borlaug","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2026.103310_bib79","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.117.032094","article-title":"Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): a phase 2, randomized, sham-controlled trial","volume":"137","author":"Feldman","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib80","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","article-title":"Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial","volume":"9","author":"Burkhoff","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib81","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","article-title":"The beta-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction","volume":"124","author":"Reddy","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2026.103310_bib82","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.123.067971","article-title":"Cardiovascular effects of oral ketone ester treatment in patients with heart failure with reduced ejection fraction: a randomized, controlled, double-blind trial","volume":"149","author":"Berg-Hansen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib83","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.124.069732","article-title":"Randomized crossover trial of 2-week ketone ester treatment in patients with type 2 diabetes and heart failure with preserved ejection fraction","volume":"150","author":"Gopalasingam","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib84","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamacardio.2024.2612","article-title":"Endovascular ablation of the greater splanchnic nerve in heart failure with preserved ejection fraction: the REBALANCE-HF randomized clinical trial","volume":"9","author":"Fudim","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib85","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1161\/01.CIR.94.12.3176","article-title":"Hemodynamic exercise testing. A valuable tool in the selection of cardiac transplantation candidates","volume":"94","author":"Chomsky","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ejhf.2747","article-title":"Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea","volume":"25","author":"Omote","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2019.10.048","article-title":"Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib88","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004750","article-title":"Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure","volume":"11","author":"Eisman","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib89","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehaf027","article-title":"Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"46","author":"Doi","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.103310_bib90","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2023.0675","article-title":"Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial","volume":"329","author":"Reddy","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2026.103310_bib91","article-title":"The uses of right heart catheterization in cardio-pulmonary disease: state-of-the-art","volume":"49","author":"Katbamna","year":"2025","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.jchf.2026.103310_bib92","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib93","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib94","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ejhf.2848","article-title":"Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society","volume":"25","author":"Tsutsui","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib95","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2026.103310_bib96","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCHEARTFAILURE.111.962290","article-title":"Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to medicare claims","volume":"4","author":"Kociol","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib97","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000806","article-title":"B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes","volume":"3","author":"Flint","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jchf.2026.103310_bib98","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jacc.2019.06.055","article-title":"Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction","volume":"74","author":"Januzzi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib99","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-9149(03)00741-0","article-title":"Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure","volume":"92","author":"Wu","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib100","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ahj.2006.08.021","article-title":"Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results","volume":"152","author":"Wu","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2026.103310_bib101","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1373\/49.9.1554","article-title":"Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals","volume":"49","author":"Melzi d\u2019Eril","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.jchf.2026.103310_bib102","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1373\/clinchem.2004.038752","article-title":"High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure","volume":"50","author":"Bruins","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.jchf.2026.103310_bib103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cardfail.2006.09.003","article-title":"The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients","volume":"13","author":"O\u2019Hanlon","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib104","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.amjcard.2006.06.017","article-title":"Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure","volume":"98","author":"Ara\u00fajo","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.cardfail.2005.04.006","article-title":"NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality","volume":"11","author":"Bay\u00e9s-Gen\u00eds","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib106","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib107","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2459\/JCM.0b013e3282f447ae","article-title":"NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients","volume":"9","author":"Verdiani","year":"2008","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.jchf.2026.103310_bib108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/heartjnl-2013-303632","article-title":"A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on acute decompeNsated heart failure: ELAN-HF score","volume":"100","author":"Salah","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2026.103310_bib109","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jacc.2008.04.069","article-title":"Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)","volume":"52","author":"Masson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jchf.2023.11.007","article-title":"Prognostic impact of repeated NT-proBNP measurements in patients with heart failure with reduced ejection fraction","volume":"12","author":"Fuery","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib112","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103310_bib113","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/heartjnl-2018-314173","article-title":"Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction","volume":"105","author":"Salah","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2026.103310_bib114","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.jacc.2019.01.072","article-title":"Exercise intolerance in patients with heart failure: JACC state-of-the-art review","volume":"73","author":"Del Buono","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/CIRCULATIONAHA.106.184461","volume":"116","author":"Arena","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib116","unstructured":"U.S. Food and Drug Administration. Treatment for Heart Failure, Endpoints for Drug Development Guidance for Industry, 2019. Accessed August 25, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry"},{"key":"10.1016\/j.jchf.2026.103310_bib117","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/CIR.0b013e3181e52e69","article-title":"Clinician\u2019s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association","volume":"122","author":"Balady","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib118","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1161\/CIR.0000000000000461","article-title":"Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association","volume":"134","author":"Ross","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib119","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cpcardiol.2015.01.009","article-title":"Cardiopulmonary exercise testing in heart failure","volume":"40","author":"Myers","year":"2015","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jchf.2016.03.022","article-title":"Cardiopulmonary exercise testing in heart failure","volume":"4","author":"Malhotra","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib121","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jchf.2020.03.008","article-title":"Impaired exercise tolerance in heart failure with preserved ejection fraction: quantification of multiorgan system reserve capacity","volume":"8","author":"Nayor","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib122","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.hjr.0000189807.22224.54","article-title":"Prognostic value of time-related changes of cardiopulmonary exercise testing indices in stable chronic heart failure: a pragmatic and operative scheme","volume":"13","author":"Corra","year":"2006","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.jchf.2026.103310_bib123","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib124","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008970","article-title":"Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF","volume":"15","author":"Lewis","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jchf.2022.09.012","article-title":"Functional and symptomatic clinical trial endpoints: the HFC-ARC scientific expert panel","volume":"10","author":"Psotka","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib126","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2011.09.027","article-title":"Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure","volume":"163","author":"Flynn","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2026.103310_bib127","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mayocp.2023.08.031","article-title":"Inorganic nitrite to amplify the benefits and tolerability of exercise training in heart failure with preserved ejection fraction: the INABLE-training trial","volume":"99","author":"Borlaug","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jchf.2026.103310_bib128","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019864","article-title":"Discordance between severity of heart failure as determined by patient report versus cardiopulmonary exercise testing","volume":"10","author":"Michelis","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jchf.2026.103310_bib129","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/s41591-025-03671-1","article-title":"Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency","volume":"31","author":"Anker","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2026.103310_bib130","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cardfail.2022.10.423","article-title":"Minimal clinically important differences in 6-minute walk test in patients with HFrEF and iron deficiency","volume":"29","author":"Khan","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102660","article-title":"Semaglutide and exercise function in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"13","author":"Borlaug","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib132","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2009.454","article-title":"Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial","volume":"301","author":"O\u2019Connor","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2026.103310_bib133","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2026.103310_bib134","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cardfail.2024.01.016","article-title":"Wearable sensors to monitor physical activity in heart failure clinical trials: state-of-the-art review","volume":"30","author":"Buendia","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib135","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103310_bib136","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.mayocp.2022.05.009","article-title":"Effects of replacing sedentary time with physical activity on mortality among patients with heart failure: National Health and Nutrition Examination Survey follow-up study","volume":"97","author":"Kim","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jchf.2026.103310_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315575","article-title":"Validity of the Actigraph-GT9X accelerometer for measuring steps and energy expenditures in heart failure patients","volume":"19","author":"Kim","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2026.103310_bib138","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2023.09.050","article-title":"Objectively measured night-time sleep efficiency and quality of life in patients with heart failure with preserved ejection fraction","volume":"208","author":"Ahmed","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib139","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jchf.2023.05.033","article-title":"Association between wearable device measured activity and patient-reported outcomes for heart failure","volume":"11","author":"Golbus","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib140","series-title":"Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry","year":"2019"},{"key":"10.1016\/j.jchf.2026.103310_bib141","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1054\/jcaf.2000.9503","article-title":"Preferences for treatment outcomes in patients with heart failure: symptoms versus survival","volume":"6","author":"Stanek","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib142","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1053-2498(01)00298-4","article-title":"Preferences for quality of life or survival expressed by patients with heart failure","volume":"20","author":"Lewis","year":"2001","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jchf.2026.103310_bib143","series-title":"Clinical Outcome Assessments (COA) Qualification Submissions Office of Cardiology H, Endocrinology, and Nephrology (OCEHM) Division of Cardiovascular and Nephrology (DCN), DDT COA #000084: Kans City Cardiomyopathy Questionnaire (KCCQ)","year":"2020"},{"key":"10.1016\/j.jchf.2026.103310_bib144","series-title":"Statement from FDA Commission Scott Gotlieb, MDM, on New Steps to Advance Medical Device Innovation and Help Patients Gain Faster Access to Beneficial Technologies","year":"2017"},{"key":"10.1016\/j.jchf.2026.103310_bib145","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cardfail.2024.09.019","article-title":"The rise of patient-reported outcome measures: trends in heart failure clinical trials","volume":"31","author":"Khan","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib146","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: JACC State-of-the-Art Review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib147","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","article-title":"Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib148","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2005.11.021","article-title":"Health status identifies heart failure outpatients at risk for hospitalization or death","volume":"47","author":"Heidenreich","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib149","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of serial Kansas City cardiomyopathy questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib150","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/01.CIR.0000136991.85540.A9","article-title":"Prognostic value of health status in patients with heart failure after acute myocardial infarction","volume":"110","author":"Soto","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib151","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cardfail.2024.08.061","article-title":"The Kansas City cardiomyopathy questionnaire in relation to New York Heart Association class","volume":"31","author":"Sherrod","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib152","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14319","article-title":"Comparison of patient self-reported health status with clinician-assigned New York Heart Association classification","volume":"3","author":"Tran","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jchf.2026.103310_bib153","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s11136-016-1267-9","article-title":"Quantifying clinical change: discrepancies between patients\u2019 and providers\u2019 perspectives","volume":"25","author":"Dreyer","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jchf.2026.103310_bib154","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1161\/CIRCULATIONAHA.106.670901","article-title":"Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments","volume":"115","author":"Kosiborod","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2026.103310_bib155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamacardio.2024.4266","article-title":"Validation of the Kansas City cardiomyopathy questionnaire in patients with tricuspid regurgitation","volume":"10","author":"Arnold","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib156","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCHEARTFAILURE.112.970053","article-title":"Use of the Kansas City cardiomyopathy questionnaire for monitoring health status in patients with aortic stenosis","volume":"6","author":"Arnold","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib157","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City cardiomyopathy questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib158","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359","article-title":"Comparable performance of the Kansas City cardiomyopathy questionnaire in patients with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Joseph","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103310_bib159","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamacardio.2024.4470","article-title":"Interpreting population mean treatment effects in the Kansas City cardiomyopathy questionnaire: a patient-level meta-analysis","volume":"10","author":"Abdel Jawad","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib160","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jacc.2024.02.019","article-title":"Variation in health status with invasive vs conservative management of chronic coronary disease","volume":"83","author":"Arnold","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103310_bib161","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.124.010923","article-title":"Developing an individualized patient decision aid for chronic coronary disease based on the ISCHEMIA trial: a mixed-methods study","volume":"17","author":"Nguyen","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2026.103310_bib162","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004111","article-title":"Precision medicine for cardiac resynchronization: predicting quality of life benefits for individual patients-an analysis from 5 clinical trials","volume":"10","author":"Nassif","year":"2017","journal-title":"Circ Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926004130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926004130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:20:10Z","timestamp":1791256810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177926004130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":162,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2213177926004130"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103310","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining Clinically Meaningful Within-Patient Changes in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103310"}}